Lumeon appoints executive chair to its board

Digital health company Lumeon has appointed Tom Zajac to its board of directors as executive chair.

He will be replacing Dr Carl Schramm who is stepping down from the role and will continue as an advisor to the company and work with the board and management team.

Zajac brings more than 35 years of industry experience managing public and private healthcare companies. 

Tom Zajac

He is an executive in residence and limited partner for investment firms Noro Moseley Partners and Summit Partners, a board director and advisor to Jvion Health, and an investor and advisor to several early-stage companies. 

Zajac previously served as chief executive officer of Population Health at healthtech company Philips, president and CEO of Wellcentive, chief customer officer at Elsevier, and CEO of CareScience. He is a senior scholar in the Jefferson School of Population Health, and a board member and advisor for several health technology companies.

‘Tom’s deep experience in healthcare transformation, having built and led multiple public and private healthcare technology companies through rapid growth, delivering patient-centered outcomes and industry-leading customer satisfaction, will be invaluable to Lumeon as we continue to grow our business and pursue our mission to ensure the safe, scalable delivery of the right care to the right patient, every time,’ said Robbie Hughes, founder and CEO of Lumeon. 

Founded in 2005 with offices in Boston and London, Lumeon provides a care pathway management platform to enable healthcare organisations to automate systems and processes that deliver better outcomes. 

Its platform is used in 12 countries across 2,000 healthcare sites, reaching 11 million patients.

In November, the digital health company raised US$30m in a Series D funding round to extend the reach of its care pathway platform.

The round was led by new investors Optum Ventures and Endeavour Vision, with participation from current investors LSP, MTIP, IPF Partners, Gilde and Amadeus Capital Partners.